Your browser is no longer supported. Please, upgrade your browser.
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own3.50% Shs Outstand42.80M Perf Week198.69%
Market Cap873.10M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float37.16M Perf Month201.66%
Income-57.00M PEG- EPS next Q-0.27 Inst Own66.10% Short Float1.85% Perf Quarter328.71%
Sales6.00M P/S145.52 EPS this Y-10.10% Inst Trans3.07% Short Ratio0.25 Perf Half Y713.39%
Book/sh0.95 P/B19.18 EPS next Y16.40% ROA-64.10% Target Price20.00 Perf Year1038.75%
Cash/sh1.11 P/C16.35 EPS next 5Y- ROE-103.50% 52W Range0.70 - 24.28 Perf YTD181.61%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-24.96% Beta1.36
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin18.70% 52W Low2502.86% ATR1.96
Employees77 Current Ratio4.50 Sales Q/Q40.00% Oper. Margin- RSI (14)86.35 Volatility24.15% 13.24%
OptionableYes Debt/Eq0.27 EPS Q/Q55.50% Profit Margin- Rel Volume0.50 Prev Close18.04
ShortableYes LT Debt/Eq0.26 EarningsNov 04 BMO Payout- Avg Volume2.79M Price18.22
Recom1.20 SMA20119.85% SMA50224.38% SMA200497.00% Volume1,385,070 Change1.00%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Jan-20-21 01:25PM  
12:13PM  
10:30AM  
08:45AM  
07:32AM  
04:19AM  
Jan-19-21 04:34PM  
04:01PM  
12:10PM  
07:00AM  
Dec-28-20 11:17PM  
Dec-23-20 09:11AM  
Dec-15-20 11:26PM  
07:00AM  
Nov-16-20 04:01PM  
Nov-14-20 07:08AM  
Nov-06-20 12:00PM  
Nov-04-20 08:25AM  
07:00AM  
Oct-29-20 12:35PM  
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
07:00AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
01:42PM  
Oct-07-19 07:25AM  
Oct-06-19 10:00AM  
Oct-03-19 07:28AM  
Sep-30-19 12:15PM  
10:44AM  
Sep-28-19 06:30PM  
10:00AM  
Sep-27-19 08:15PM  
03:00PM  
12:21PM  
11:00AM  
10:36AM  
Sep-26-19 04:45PM  
04:45PM  
11:17AM  
08:19AM  
Sep-25-19 08:48PM  
03:38PM  
03:15PM  
11:00AM  
10:35AM  
09:00AM  
Sep-24-19 09:10PM  
03:15PM  
03:09PM  
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.